|
119th CONGRESS
1st Session |
Urging the Director of the Food and Drug Administration to reevaluate the safety of all chemical abortion drugs in light of recent independent studies, and for other purposes.
Mr. Rose (for himself, Mrs. Harshbarger, Mr. Carter of Georgia, Mr. LaMalfa, Mrs. Biggs of South Carolina, Mr. Moore of Alabama, Ms. Hageman, and Mr. Grothman) submitted the following resolution; which was referred to the Committee on Energy and Commerce
Urging the Director of the Food and Drug Administration to reevaluate the safety of all chemical abortion drugs in light of recent independent studies, and for other purposes.
Whereas the Obama administration expanded access to chemical abortion drugs by removing in-person administration requirements, eliminating requirements for prescribers to report serious adverse effects, and removing follow-up care obligations;
Whereas the Biden administration further expanded access to chemical abortion drugs by removing in-person dispensing requirements, permitting these drugs to be distributed by mail;
Whereas the expansion of access to chemical abortion drugs has raised serious concerns regarding potential violations of Federal law, increased risks of coercion and domestic abuse, and even intentional misuse resulting in harm or death;
Whereas chemical abortions now account for more than half of all abortions performed in the United States;
Whereas many providers prescribing chemical abortion drugs receive taxpayer funding, raising ethical and legal concerns regarding the use of public funds;
Whereas, on September 30, 2025, the Food and Drug Administration approved a new generic version of mifepristone, further expanding the availability of chemical abortion drugs;
Whereas this approval will likely contribute to a significant increase in the number of unborn children lost to abortion, and poses a risk of potential physical and emotional harm to women and girls, while undermining pro-life laws enacted by numerous States; and
Whereas independent research suggests that chemical abortions carry a rate of serious complications that is 22 times higher than what is currently reported by the Food and Drug Administration and drug manufacturers: Now, therefore, be it
Resolved, That the House of Representatives urges the Director of the Food and Drug Administration—
(1) to reevaluate the safety of all chemical abortion drugs in light of recent independent studies; and
(2) to publicly release a full safety review of such drugs that includes real-world outcomes and complications.